Prevalence and Profile of Aspirin Resistance in Hemodialysis Patients

This study has been completed.

Sponsored by:	Staten Island University Hospital
Information provided by:	Staten Island University Hospital
ClinicalTrials.gov Identifier:	NCT00792272

Purpose

Dialysis patient could be more aspirin resistant than the general population based on data from chronic kidney disease patients

Condition
Aspirin Resistance

MedlinePlus related topics: Dialysis Kidney Failure

Drug Information available for: Acetylsalicylic acid

U.S. FDA Resources

Study Type:	Observational
Official Title:	Prevalence of Aspirin Resistance in Hemodialysis Patients

Further study details as provided by Staten Island University Hospital:

Study Start Date:	June 2008
Study Completion Date:	November 2008
Primary Completion Date:	November 2008 (Final data collection date for primary outcome measure)

Detailed Description:

We will try to describe the profile of aspirin resistant patient in hemodialysis patients

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

all hemodialysis patients on aspirin

Criteria

Inclusion Criteria:

all hemodialysis patients on aspirin

Exclusion Criteria:

low platelets <100.000
coagulopathy, bleeding disorders
patient on plavix

Contacts and Locations

No Contacts or Locations Provided

More Information

Responsible Party:	staten island university hospital ( Suzanne El-Sayegh )
Study ID Numbers:	08-013
Study First Received:	November 14, 2008
Last Updated:	November 14, 2008
ClinicalTrials.gov Identifier:	NCT00792272
Health Authority:	United States: Institutional Review Board

Keywords provided by Staten Island University Hospital:

aspirin resistance
aspirin resistance in hemodialysis patients

Study placed in the following topic categories:

Aspirin

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Molecular Mechanisms of Pharmacological Action
Cyclooxygenase Inhibitors
Hematologic Agents
Physiological Effects of Drugs
Enzyme Inhibitors
Fibrinolytic Agents
Cardiovascular Agents
Pharmacologic Actions
Fibrin Modulating Agents

Analgesics, Non-Narcotic
Sensory System Agents
Therapeutic Uses
Platelet Aggregation Inhibitors
Anti-Inflammatory Agents, Non-Steroidal
Analgesics
Peripheral Nervous System Agents
Antirheumatic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 15, 2009